14 Chapter 1 References [1] Integraal Kankercentrum Nederland. Slokdarm- en maagkanker in Nederland 2021:1–48. [2] van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84. https://doi.org/10.1056/NEJMoa1112088. [3] Langendijk J a, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013;107:267–73. https://doi.org/10.1016/j.radonc.2013.05.007. [4] Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyenberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Disagnosis (TRIPOD): Explanantion and Elaboration. Ann Intern Med 2015;162:W1–74. https://doi.org/10.7326/M140698. [5] Defraene G, Schuit E, De Ruysscher D. Development and internal validation of a multinomial NTCP model for the severity of acute dyspnea after radiotherapy for lung cancer. Radiother Oncol 2019;136:176–84. https://doi.org/10.1016/j.radonc.2019.03.034. [6] KWA SLS. JVL. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998;42:1–9. [7] Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol (Madr) 2012;51:975–83. https://doi.org/10.3109/0 284186X.2012.718093. [8] Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21:3431–9. https://doi.org/10.1200/JCO.2003.07.131. [9] McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson N-O, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011;100:167–75. https://doi.org/10.1016/j.radonc.2011.06.016. [10] Aleman BMP, Van Den Belt-Dusebout AW, De Bruin ML, Van ’t Veer MB, Baaijens MHA, De Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–86. https://doi.org/10.1182/blood-2006-07-034405. [11] Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. https://doi.org/10.1056/NEJMoa1209825. [12] Van Den Bogaard VAB, Ta BDP, Van Der Schaaf A, Bouma AB, Middag AMH, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol 2017;35:1171–8. https://doi.org/10.1200/JCO.2016.69.8480. [13] “Port Meta-analysis Trialists group.” Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257–63. [14] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 2015;16:187–99. https://doi. org/10.1016/S1470-2045(14)71207-0. [15] Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer. J Thorac Oncol 2017;12:293–301. https://doi.org/10.1016/j.jtho.2016.09.134. [16] Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol 2019;73:2976–87. https://doi.org/10.1016/j.jacc.2019.03.500.
RkJQdWJsaXNoZXIy MTk4NDMw